Journal Article DKFZ-2022-01135

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Five-year symptomatic hemorrhage risk of untreated brainstem cavernous malformations in a prospective cohort.

 ;  ;  ;  ;  ;  ;  ;  ;  ;

2022
Springer New York

Neurosurgical review 45(4), 2961-2973 () [10.1007/s10143-022-01815-2]
 GO

This record in other databases:

Please use a persistent id in citations: doi:

Abstract: Hemorrhage of brainstem cavernous malformation (CM) would cause various symptoms and severe disability. The study aimed to elaborate on the 5-year actuarial cumulative hazard of symptomatic hemorrhage. Patients diagnosed in our institute between 2009 and 2013 were prospectively registered. All clinical data were obtained, follow-up was performed, and risk factors were evaluated. Four hundred sixty-eight patients (217 female, 46.4%) were included in the study with a median follow-up duration of 79.0 months. A total of 137 prospective hemorrhages occurred in 107 patients (22.9%) during 1854.0 patient-years. Multivariate Cox analysis found age ≥ 55 years (hazard ratio (HR) 2.166, p = 0.002), DVA (HR 1.576, p = 0.026), superficial-seated location (HR 1.530, p = 0.047), and hemorrhage on admission (HR 2.419, p = 0.026) as independent risk factors for hemorrhage. The 5-year cumulative hazard of hemorrhage was 30.8% for the overall cohort, 47.8% for 60 patients with age ≥ 55 years, 43.7% for 146 patients with DVA, 37.9% for 272 patients with superficial-seated lesions, and 37.2% for 341 patients with hemorrhage on admission. As a stratified analysis, within subcohort of 341 patients with a hemorrhagic presentation, age ≥ 55 years (HR 3.005, p < 0.001), DVA (HR 1.801, p = 0.010), and superficial-seated location (HR 2.276, p = 0.001) remained independently significant. The 5-year cumulative hazard of hemorrhage was 52.0% for 119 patients with both DVA and hemorrhagic presentation. The 5-year cumulative hemorrhagic risk was 30.8% and was higher in subgroups if harboring risk factors that helped to predict potential hemorrhagic candidates and were useful for treatment decision-making.Clinical Trial Registration-URL: http://www.chictr.org.cn Unique identifier: ChiCTR-POC-17011575.

Keyword(s): Brainstem cavernous malformation ; Cavernoma ; Cerebral cavernous malformation ; Hemorrhage risk ; Natural history

Classification:

Note: 2022 Aug;45(4):2961-2973

Contributing Institute(s):
  1. A240 Molekulare Neurogenetik (A240)
Research Program(s):
  1. 311 - Zellbiologie und Tumorbiologie (POF4-311) (POF4-311)

Appears in the scientific report 2022
Database coverage:
Medline ; Clarivate Analytics Master Journal List ; DEAL Springer ; Ebsco Academic Search ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Public records
Publications database

 Record created 2022-05-31, last modified 2024-02-29



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)